Journal of Ginseng Research

The Korean Society of Ginseng (고려인삼학회)
권호 표지
DOI QR코드

DOI QR Code

Ginseng-plus-Bai-Hu-Tang ameliorates diet-induced obesity, hepatic steatosis, and insulin resistance in mice

  • Lu, Hsu-Feng (Departments of Clinical Pathology, Cheng Hsin General Hospital) ;
  • Lai, Yu-Heng (Department of Chemistry, Chinese Culture University) ;
  • Huang, Hsiu-Chen (Department of Applied Science, National Tsing Hua University South Campus) ;
  • Lee, I-Jung (Department of Kampo Medicine, Yokohama University of Pharmacy) ;
  • Lin, Lie-Chwen (National Research Institute of Chinese Medicine, Ministry of Health and Welfare) ;
  • Liu, Hui-Kang (National Research Institute of Chinese Medicine, Ministry of Health and Welfare) ;
  • Tien, Hsiao-Hsuan (Department of Biotechnology and Laboratory Science in Medicine, National Yang-Ming University) ;
  • Huang, Cheng (Department of Biotechnology and Laboratory Science in Medicine, National Yang-Ming University)
  • Received : 2018.04.26
  • Accepted : 2018.10.22
  • Published : 2020.03.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Dietary fat has been suggested to be the cause of various health issues. Obesity, hypertension, cardiovascular disease, diabetes, dyslipidemia, and kidney disease are known to be associated with a high-fat diet (HFD). Obesity and associated conditions, such as type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD), are currently a worldwide health problem. Few prospective pharmaceutical therapies that directly target NAFLD are available at present. A Traditional Chinese Medicine, ginseng-plus-Bai-Hu-Tang (GBHT), is widely used by diabetic patients to control glucose level or thirst. However, whether it has therapeutic effects on fat-induced hepatic steatosis and metabolic syndrome remains unclear. Methods: This study was conducted to examine the therapeutic effect of GBHT on fat-induced obesity, hepatic steatosis, and insulin resistance in mice. Results: GBHT protected mice against HFD-induced body weight gain, hyperlipidemia, and hyperglycemia compared with mice that were not treated. GBHT inhibited the expansion of adipose tissue and adipocyte hypertrophy. No ectopic fat deposition was found in the livers of HFD mice treated with GBHT. In addition, glucose intolerance and insulin sensitivity in HFD mice was also improved by GBHT. Conclusion: GBHT prevents changes in lipid and carbohydrate metabolism in a HFD mouse model. Our findings provide evidence for the traditional use of GBHT as therapy for the management of metabolic syndrome.

Keywords

References

  1. Johnson RJ, et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr 2007;86(4):899-906.
  2. Fraulob JC, et al. A mouse model of metabolic syndrome: insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFPD) in C57BL/6 mice fed a high fat diet. J Clin Biochem Nutr 2010;46(3):212-23. https://doi.org/10.3164/jcbn.09-83
  3. Podrini C, et al. High-fat feeding rapidly induces obesity and lipid derangements in C57BL/6N mice. Mamm Genome 2013;24(5-6):240-51. https://doi.org/10.1007/s00335-013-9456-0
  4. Dunn W, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008;103(9):2263-71. https://doi.org/10.1111/j.1572-0241.2008.02034.x
  5. Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2010;3(2):121-37. https://doi.org/10.1177/1756283X09359964
  6. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008;118(3):829-38. https://doi.org/10.1172/JCI34275
  7. Masuoka, H.C. and N. Chalasani, Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci. 1281: p. 106-122. https://doi.org/10.1111/nyas.12016
  8. Smith, B.W. and L.A. Adams, Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol. 7(8): p. 456-465. https://doi.org/10.1038/nrendo.2011.72
  9. Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J 2006;82(967):315-22. https://doi.org/10.1136/pgmj.2005.042200
  10. Nobili V, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008;48(1):119-28. https://doi.org/10.1002/hep.22336
  11. Chen CC, et al. Peroxisome proliferator-activated receptor gamma transactivation-mediated potentiation of glucose uptake by Bai-Hu-Tang. J Ethnopharmacol 2008;118(1):46-50. https://doi.org/10.1016/j.jep.2008.03.001
  12. Huang CY, et al. Prescription pattern of Chinese herbal products for diabetes mellitus in taiwan: a population-based study. Evid Based Complement Alternat Med 2013;2013:201329.
  13. Kimura I, et al. The antihyperglycaemic blend effect of traditional Chinese medicine byakko-ka-ninjin-to on alloxan and diabetic KK-CA(y) mice. Phytother Res 1999;13(6):484-8. https://doi.org/10.1002/(SICI)1099-1573(199909)13:6<484::AID-PTR485>3.0.CO;2-X
  14. Liu HK, et al. Ginseng-plus-Bai-Hu-Tang decoction reduces fatty liver by activating AMP-activated protein kinase in vitro and in vivo. Evid Base Compl Alternat Med 2015;2015:651734.
  15. Kawamoto TH, et al. Resting metabolic rates of two orbweb spiders: a first approach to evolutionary success of ecribellate spiders. J Insect Physiol 2011;57(3):427-32. https://doi.org/10.1016/j.jinsphys.2011.01.001
  16. Suliga E, et al. Factors associated with adiposity, lipid profile disorders and the metabolic syndrome occurrence in premenopausal and postmenopausal women. PLoS One 2016;11(4):e0154511. https://doi.org/10.1371/journal.pone.0154511
  17. Zambo, V., et al., Lipotoxicity in the liver. World J Hepatol. 5(10): p. 550-557. https://doi.org/10.4254/wjh.v5.i10.550
  18. Fabbrini E, Magkos F. Hepatic steatosis as a marker of metabolic dysfunction. Nutrients 2015;7(6):4995-5019. https://doi.org/10.3390/nu7064995
  19. Cassidy WM, Reynolds TB. Serum lactic dehydrogenase in the differential diagnosis of acute hepatocellular injury. J Clin Gastroenterol 1994;19(2):118-21. https://doi.org/10.1097/00004836-199409000-00008
  20. Dufour DR, et al. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000;46(12):2050-68. https://doi.org/10.1093/clinchem/46.12.2050
  21. Giordano C, et al. Uric acid as a marker of kidney disease: review of the current literature. Dis Markers 2015;2015:382918. https://doi.org/10.1155/2015/382918
  22. Sato A, et al. Antiobesity effect of eicosapentaenoic acid in high-fat/highsucrose diet-induced obesity: importance of hepatic lipogenesis. Diabetes 2010;59(10):2495-504. https://doi.org/10.2337/db09-1554
  23. Ling JC, et al. Determinants of high fasting insulin and insulin resistance among overweight/obese adolescents. Sci Rep 2016;6:36270. https://doi.org/10.1038/srep36270
  24. Xiong, Y., et al., Antiobesity and antihyperglycemic effects of ginsenoside Rb1 in rats. Diabetes. 59(10): p. 2505-2512. https://doi.org/10.2337/db10-0315
  25. Park S, et al. Ginsenosides Rb1 and Rg1 suppress triglyceride accumulation in 3T3-L1 adipocytes and enhance beta-cell insulin secretion and viability in Min6 cells via PKA-dependent pathways. Biosci Biotechnol Biochem 2008;72(11):2815-23. https://doi.org/10.1271/bbb.80205
  26. Shen, L., et al., Ginsenoside Rb1 reduces fatty liver by activating AMPactivated protein kinase in obese rats. J Lipid Res. 54(5): p. 1430-1438. https://doi.org/10.1194/jlr.M035907
  27. Srinivasan K, et al. Combination of high-fat diet-fed and low-dose streptozotocin- treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 2005;52(4):313-20. https://doi.org/10.1016/j.phrs.2005.05.004
  28. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 2007;176(8):1113-20. https://doi.org/10.1503/cmaj.060963
  29. Jialal I, Amess W, Kaur M. Management of hypertriglyceridemia in the diabetic patient. Curr Diab Rep 2010;10(4):316-20. https://doi.org/10.1007/s11892-010-0124-4
  30. Tomlinson JW, et al. Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. Diabetes 2008;57(10):2652-60. https://doi.org/10.2337/db08-0495
  31. Morimoto A, et al. Increase in homeostasis model assessment of insulin resistance (HOMA-IR) had a strong impact on the development of type 2 diabetes in Japanese individuals with impaired insulin secretion: the Saku study. PLoS One 2014;9(8):e105827. https://doi.org/10.1371/journal.pone.0105827
  32. Pataky MW, et al. High-fat diet-induced insulin resistance in single skeletal muscle fibers is fiber type selective. Sci Rep 2017;7(1):13642. https://doi.org/10.1038/s41598-017-12682-z
  33. Hancock CR, et al. High-fat diets cause insulin resistance despite an increase in muscle mitochondria. Proc Natl Acad Sci U S A 2008;105(22):7815-20. https://doi.org/10.1073/pnas.0802057105
  34. Cheng J, et al. Loss of Mbd2 protects mice against high-fat diet-induced obesity and insulin resistance by regulating the homeostasis of energy storage and expenditure. Diabetes 2016;65(11):3384-95. https://doi.org/10.2337/db16-0151
  35. Enomoto H, et al. Liver fibrosis markers of nonalcoholic steatohepatitis. World J Gastroenterol 2015;21(24):7427-35. https://doi.org/10.3748/wjg.v21.i24.7427
  36. Armutcu F, et al. Markers in nonalcoholic steatohepatitis. Adv Clin Chem 2013;61:67-125. https://doi.org/10.1016/B978-0-12-407680-8.00004-X
  37. Regev A, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97(10):2614-8. https://doi.org/10.1016/S0002-9270(02)04396-4
  38. Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol 2014;20(45):16820-30. https://doi.org/10.3748/wjg.v20.i45.16820

Cited by

  1. Effect of Korean Red Ginseng through comparative analysis of cardiac gene expression in db/db mice vol.45, pp.3, 2020, https://doi.org/10.1016/j.jgr.2020.06.001
  2. Effect of Korean Red Ginseng on metabolic syndrome vol.45, pp.3, 2020, https://doi.org/10.1016/j.jgr.2020.11.002
  3. The effects of ginseng on the metabolic syndrome: An updated review vol.9, pp.9, 2021, https://doi.org/10.1002/fsn3.2475